Genmab A/S
Genmab A/S is a Denmark-based biotechnology company focused on discovering and developing antibody medicines for cancer and other serious diseases. Its business spans approved therapies, partnered programs, and a pipeline of next-generation antibody formats, with international operations across North America, Europe, and Asia Pacific.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2022–2025
Liiketoiminta
Osuus liikevaihdostaRoyalty income from partner sales of approved antibody medicines.
Sales of Genmab-linked products and collaboration-linked commercial revenue.
Commercial and development milestones plus R&D reimbursement from partners.
Partnered discovery, development, and licensing arrangements for antibody assets.
Asiakkaat
Genmab sells primarily to biopharmaceutical partners, where revenue comes from royalties, product-related collaboration income, milestones, and reimbursements tied to development and commercialization agreements. Its therapeutic products ultimately serve oncology and serious-disease patients through healthcare providers, but the direct economic buyers are usually large pharma partners and licensees. The company’s model depends on the success of partner-led commercialization as well as adoption of its own product contributions such as EPKINLY.
Large biotech and pharma companies that license, develop, and commercialize Genmab antibodies and pay royalties, milestones, or reimbursements.
Hospitals, cancer centers, and infusion clinics that administer partner-commercialized antibody medicines to patients.
End patients benefiting from approved therapies such as antibody-based cancer medicines.
Partners sharing development costs and programs in exchange for pipeline access and commercial rights.
Strategia
Genmab’s strategy centers on advancing antibody medicines from discovery through late-stage development and commercial partnerships, with a growing emphasis on its own and partnered oncology assets. The company is extending its platform across bispecific antibodies, ADCs, and immune-modulating formats while building a larger base of royalty and product revenue. It also relies on global partnerships to broaden commercial reach and convert pipeline programs into durable revenue streams.
Epcoritamab is a core growth asset and can expand across multiple B-cell malignancy settings.
A broader mix lowers dependence on any single product and improves monetization of the antibody platform.
Bispecifics, ADCs, and immune-modulating antibodies deepen the pipeline and improve long-term optionality.
Maantiede
Genmab is headquartered in Copenhagen and operates internationally across North America, Europe, and Asia Pacific. Its economic exposure is concentrated in the U.S. through partnered oncology commercialization, while Denmark remains the corporate and R&D center. The company’s revenue base is geographically diversified through partner sales and royalty streams tied to global medicine launches.
Riskit
Genmab depends on the clinical and commercial success of a relatively concentrated set of antibody assets and partner programs, so pipeline setbacks or slower-than-expected uptake can affect growth. Because much of revenue comes from royalties and collaboration arrangements, the company is exposed to partner execution, pricing pressure, and regulatory risk across multiple markets. As a biotech company with significant intangible assets and global operations, it also faces valuation, impairment, and foreign-exchange-related accounting and business risks.
- Concentration in a small number of oncology assetsVaikutus: KorkeaTodennäköisyys: Korkea
Revenue and pipeline value rely heavily on a few approved and late-stage antibody programs.
Kohdistuu - Partner commercialization and pricing riskVaikutus: KorkeaTodennäköisyys: Korkea
Royalties and collaboration revenue depend on third-party launch execution, reimbursement, and pricing.
Kohdistuu: Global oncology partner sales
- Clinical and regulatory development riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Late-stage trials may fail to show efficacy or safety needed for approval and label expansion.
Kohdistuu: Epcoritamab and other pipeline programs
- Impairment of acquired intangibles and goodwillVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Biotech acquisition accounting can leave large asset balances sensitive to revised assumptions.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätRevenue is linked to partner net sales and contractual royalty rates, so timing follows third-party commercialization.
Vaikutus: Can create quarter-to-quarter swings in reported revenue
AbbVie and Gilead-related obligations are recognized as performance obligations are satisfied.
Vaikutus: Affects timing of reimbursement revenue recognition
Large biotech acquisitions create capitalized assets subject to judgmental valuation and impairment tests.
Vaikutus: Can materially affect earnings if assumptions change
Currency and other hedges can introduce fair value gains and losses.
Vaikutus: May add non-operating volatility to interim results
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Xencor Inc
XNCR · Pharmaceutical Preparations
Evaxion A/S
EVAX · Biological Products, (No Diagnostic Substances)
Evaxion A/S is a clinical-stage biotech company focused on developing vaccines and other drug candidates using its AI-Immunology™ platform.
AnaptysBio, Inc
ANAB · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
OmniAb, Inc.
OABIW · Services-Commercial Physical & Biological Research
Alvotech
ALVO · Biological Products, (No Diagnostic Substances)
Alvotech is a U.S.-listed biotechnology company focused on developing and manufacturing biosimilar medicines.
Päivitetty: 28.9.2026